All Stories

  1. Product review: avelumab, an anti-PD-L1 antibody

    Article • Human Vaccines & Immunotherapeutics, November 2018, Taylor & Francis

    James Gulley

  2. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

    Article • Expert Review of Vaccines, August 2018, Taylor & Francis

    James Gulley

  3. A new agent that targets PD-L1 and TGF-beta can reverse EMT in lung cancer cells

    Article • OncoImmunology, July 2017, Taylor & Francis

    James Gulley, Justin David

  4. Vaccines and Immunostimulants

    Article • February 2017, Wiley

    James Gulley

  5. PSA

    Article • January 2017, Springer Science + Business Media

    James Gulley

  6. GU Vaccines

    Article • Expert Opinion on Biological Therapy, September 2014, Informa Healthcare

    James Gulley

  7. The Clinical Utility of Bevacizumab

    Article • January 2008, Springer Science + Business Media

    James Gulley

  8. Pox Viral Vaccines

    Article • January 2004, Springer Science + Business Media

    James Gulley